Citations

Clear

4207 citation(s) found for "Chen, Yu".

Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract
Chiu, April , Viswanatha, David S., He, Rong , Reichard, Kaaren K. , Tefferi, Ayalew, Pardanani, Animesh , Chen, Dong , Majerus, Julie A. , Chen, Dong , Tefferi, Ayalew

Mayo Clinic

Am J Clin Pathol | September 9, 2025 | Volume: 164 | Issue: 6 | Pages: 879-889

10.1093/ajcp/aqaf112 | PMID 41293991 Get It

Abstract Objective Gastrointestinal (GI) symptoms are common in systemic mastocytosis (SM). We hereby report the clinicopathologic and molecular features of GI mastocytosis. Methods The study includes 104 patients with suspected SM. Of 258 GI biopsy ­specimens, 33 (20 patients, 19%) were mastocytosis-positive, with 19 (16 patients) initially missed. Results Tryptase (n = 29) was weakly positive/negative in two-thirds of the mastocytosis-positive GI biopsy specimens. Additional immunohistochemistry (n = 23) showed positive mast cell expression for CD30 (n = 2), CD123 (n = 7), and PD-L1 (n = 12), as well as increased PD-1–positive cells (n = 4). Sixty patients had positive bone marrow (BM) for SM (SM-BM+), including 19 with positive GI biopsy specimens (SM-GI+). Almost all (43/44) SM-BM– patients were SM-GI–. The SM-GI vs SM-BM status showed high positive predictive value (95%) and specificity (98%). Patients with SM with mastocytosis-positive vs mastocytosis-negative GI biopsy specimens had higher serum tryptase levels (P = .04). KIT D816V mutation was detected in 7 of 13 and 12 of 13 mastocytosis-positive GI biopsy specimens using allele-specific polymerase chain reaction and droplet digital polymerase chain reaction (ddPCR), respectively. Conclusions GI mastocytosis is highly predictive of SM in BM; however, most SM-BM+ patients are SM-GI–. The SM-BM– patients are very unlikely to be SM-GI+. Because GI neoplastic mast cells are often tryptase negative, diagnostic evaluation should include CD117 and CD25 immunohistochemistry, as well as KIT D816V mutation analysis by ddPCR as needed.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Torres, Joana , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla, Long, Millie D. , IBD, Global Consensus Group for Pregnancy and, Maria, Abreu, Ali, Azzam Nahla, Wafaa, Badre, Rupa, Banerjee, Sally, Bell, Susan, Connor, Iris, D, Marc, Ferrante, Emily, Feneberg, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Juliao, Fabián, Leolin, Katsidzira, Alicia, Sambuelli, Christian, Selinger, Astrid, Williams, Jessica, L Thomson, Nicole, A. Capela, Wenli, Chen, Natalie, Hayden, Chun, Lin, Brosbol, Ravnborg Anne, Njeri, Mwaura-Ruhio Treza, Lindsay, Rous, Chaparro, María , Flanagan, Emma , Friedman, Sonia , Julsgaard, Mette , Ng, Siew C , Torres, Joana , Yamamoto-Furusho, Jesus , Barnes, Edward L , Friedman, Sonia , Ng, Siew C. , Robinson, Christopher James , Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Ali, Azzam Nahla, Marc, Ferrante, Emily, Finlayson, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Wei, Shu‐Chen , Zaltman, Cyrla , Wenli, Chen, Lindsay, Rous

Mayo Clinic

Journal of Crohn’s and Colitis | September 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf129 | PMID 40914850 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Omics in Nonsteroidal Anti‐Inflammatory Drugs‐Exacerbated Respiratory Disease: Current Evidence From the Upper and Lower Airways
iAkushev, Aleksandr , Szatkowski, Piotr , Vorobjeva, M. A. , Chen, C.‐C. , Jerschow, Elina , Mastalerz, Lucyna , Vorobeva, Maria , Chen, Chien-Chang , Jerschow, Elina , Szatkowski, P R

Mayo Clinic

Allergy | September 5, 2025 | Volume: 81 | Issue: 1 | Pages: 56-68

10.1111/all.70034 | PMID 40908647 Get It

ABSTRACT Nonsteroidal anti‐inflammatory drugs (NSAID)‐exacerbated respiratory disease (N‐ERD) is a mainly type 2 inflammatory condition that combines asthma, nasal polyps, and hypersensitivity to NSAIDs. Its pathogenesis involves both upper and lower airways, yet most studies to date have examined these compartments separately. It remains unclear whether the molecular mechanisms in the nose, sinuses, and lungs are distinct or overlapping—an important gap, given that clinical manifestations of N‐ERD involve both sites. In this review, we summarize available omics studies—transcriptomics, proteomics, metabolomics, and epigenomics—performed on upper and lower airways in patients with N‐ERD. While omics approaches have revealed new molecular insights, comparisons across studies are limited by heterogeneity in design, controls, and methodology. We emphasize the need for integrated multi‐omics analyses and standardized frameworks to better characterize the disease across airways. Such efforts are essential for identifying robust biomarkers and therapeutic targets and for moving toward a systems‐level understanding of N‐ERD.
Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia
Cabrera-Serrano, Antonio José , Rodríguez‐Sevilla, Juan José , Reyes‐Zurita, Fernando J. , Collado, Rosa , Puiggros, Anna, Cornejo-Calvo, Elena , Horst, Rob ter , Benavente, Yolanda , Jerez, Andrés , Ramos‐Campoy, Sílvia , González‐Olmedo, Carmen , Jannus, Fatin , Marcos‐Gragera, Rafael , Carretero-Fernández, María, Sampaio‐Marques, Belém , Gámez, Irene, García‐Álvarez, María , Camp, Nicola J. , Kamaso, Joanna, Pérez, Eva María, Alcoceba, Miguel , Campa, Daniele , Sanjosé, Sílvia de , Netea, Mihai G. , McKay, James, Casabonne, Delphine , Berndt, Sonja I. , Sáinz, Juan , Rodríguez-Sevilla, Juan José , Reyes-Zurita, Fernando Jesús , Collado, Rosa , Cornejo-Calvo, Elena , Ter Horst, Rob , Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López-Nevot, Miguel Ángel , Ramos-Campoy, Silvia , Chen-Liang, Tzu-Hua , Jannus, Fatin , Marcos-Gragera, Rafael , Carretero-Fernández, María , Sampaio-Marques, Belém , Camp, Nicola J , Dierssen-Sotos, Trinidad , Kamaso, Joanna , Li, Yang , Marasca, Roberto , Ludovico, Paula , Canzian, Federico , Casabonne, Delphine , Berndt, Sonja I , Slager, Susan L , Sainz, Juan , Alcoceba, Miguel , Sánchez‐Maldonado, José Manuel , Puiggros, Anna , García-Martín, Paloma, Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López‐Nevot, Miguel Ángel , Moreno, Vı́ctor , Dierssen‐Sotos, Trinidad , Norman, Aaron D. , Luppi, Mario , Li, Yang , Marasca, Roberto , Ludovico, Paula , Clay‐Gilmour, Alyssa , Canzian, Federico , Ibáñez, Mariam , McKay, James , Slager, Susan L. , Netea, M. G.

Mayo Clinic

Blood Advances | September 3, 2025 | Volume: 9 | Issue: 23 | Pages: 6076-6089

10.1182/bloodadvances.2025017345 | PMID 40902075 Get It

Abstract We investigated the influence of 55 583 autophagy-related single-nucleotide polymorphisms (SNPs) on chronic lymphocytic leukemia (CLL) risk across 4 independent populations comprising 5472 CLL cases and 726 465 controls. We also examined their impact on overall survival (OS), time to first treatment (TTFT), autophagy flux, and immune responses. A meta-analysis of the 4 populations identified, to our knowledge, for the first time, significant associations between CDKN2A (rs3731204) and BCL2 (rs4940571, rs12457371, and rs1026825) SNPs and CLL risk, with CDKN2A showing the strongest association (P = 1.57 × 10−12). We also validated previously reported associations for FAS, BCL2, and BAK1 SNPs with CLL risk (P = 4.73 × 10−21 to 3.39 × 10−9). The CDKN2Ars3731204 and FASrs1926194 SNPs associated with increased CDKN2A and ACTA2 messenger RNA expression levels in the whole blood and/or lymphocytes (P = 5.1 × 10−7, P = 1.58 × 10−21, and P = 7.8 × 10−41), although no significant effect on autophagy flux was observed. However, associations were found between CDKN2A, BCL2, and FAS SNPs and various T-cell subsets, cytokine production, and circulating concentrations of interferon gamma, tumor necrosis factor–related apoptosis-inducing ligand, CD40, chemokine ligand 20, and interleukin-2 receptor subunit β proteins (P ≤ .005). No significant association was detected between autophagy variants and OS or TTFT, suggesting that these variants drive disease initiation rather than progression. In conclusion, this study identified 4 novel associations for CLL and provided insights into the biological pathways that influence CLL development.
Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
Polites, Stephanie F. , Aldrink, Jennifer H. , Lautz, Timothy B. , Malek, Marcus M. , Fleming, Andrew M. , Roach, Jonathan P. , Radhakrishnan, Sridharan, Piché, Nelson , Osman, Yasmin, Lovvorn, Harold N. , Favela, Juan , Marquart, John , Craig, Brian T. , Seemann, Natashia M. , Petroze, Robin T. , Rich, Barrie S. , Glick, Richard D. , Selesner, Leigh , Fialkowski, Elizabeth , Boehmer, Chloé , Malek, Marcus M , Reiter, Audra , Murphy, Andrew J , Kastenberg, Zachary J , Tracy, Elisabeth T , Seemann, Natashia M , Rich, Barrie S , Fialkowski, Elizabeth A , Lautz, Timothy , Aldrink, Jennifer H , Vierkant, Robert A. , Chen, Stephanie , Kim, Eugene S. , Rinehardt, Hannah , Murphy, Andrew J. , Radhakrishnan, Sridharan, Kastenberg, Zachary J. , Tracy, Elisabeth T. , Le, Hau D. , Lal, Dave R. , Yoo, Ashley , Brown, Erin G. , Dasgupta, Roshni , Langham, Max Raymond

Mayo Clinic

Pediatric Blood & Cancer | September 3, 2025 | Volume: 72 | Issue: 12 | Pages: No page available

10.1002/pbc.32029 | PMID 40899404 Get It

ABSTRACT Introduction Children with hepatoblastoma (HB) and other solid tumors frequently undergo intraoperative blood transfusion (IBT) with unknown impact on oncologic outcomes and scant data to guide transfusion in this population. This study tested the hypothesis that IBT is associated with poorer survival in children with HB. Methods A multicenter retrospective observational study of patients aged <18 years with HB who underwent primary tumor resection, including liver transplantation, from 2010 to 2019 was performed at 19 institutions. The association of IBT with risk of recurrence and death were determined using propensity score reweighted (PSR) Cox proportional hazards regression analyses. Results There were 338 patients identified who met inclusion criteria and had sufficient data for inclusion. Of those, 257 (76%) received IBT, including 253 (98%) who received packed red blood cells (pRBC), 84 (33%) who received plasma, and 28 (11%) who received platelets. IBT was associated with higher pretreatment extent of disease ( p < 0.001), presence of annotation factors (+VPEFR: 50%, n = 129 vs. 37%, n = 30, p = 0.035), and complex resections (extended, meso‐, or total hepatectomy: 54%, n = 139 vs. 27%, n = 22, p < 0.001); these differences were mitigated after applying propensity score weighting. Patients who received IBT had greater postoperative hemoglobin (g/dL) (median 10 (I8–11) vs. 9 (8–10), p = 0.013) and required more postoperative plasma and platelet transfusions ( p < 0.05). Median follow‐up was 4.4 (2.0–8.3) years. Compared with non‐IBT patients, those with IBT had higher incidence of death (PSR HR 2.35, 95% CI 1.10–5.02). Recurrence did not significantly differ across groups (PSR HR = 0.82, 95% CI 0.45–1.48). Conclusion IBT was associated with greater hazard of death. Postoperative hemoglobin levels suggested that unnecessary transfusions occurred and a pRBC‐focused approach to IBT led to coagulopathy. Development of optimal transfusion strategies for HB are needed to minimize unnecessary transfusions.
Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Thakolwiboon, Smathorn , Redenbaugh, Vyanka , Chen, Bo , Hewitt, S., Shah, Shailee , Lotan, Itay , Levy, Michael , Forcadela, Mirasol , Huda, Saif , Pique, Julie , Marignier, Romain , Audoin, Bertrand , Poullin, Pascale , Champsas, Dimitrios , Choi, David, Danesh‐Meyer, Helen V. , Vasileiou, Eleni S. , Sotirchos, Elias S. , Davis, James , Wilf‐Yarkoni, Adi , Bonelli, Laura , Arnold, Anthony C. , Motte, Marine Boudot de la , Deschamps, Romain , Jitprapaikulsan, Jiraporn , Moss, Heather E. , Navarro, Sylvia E. Villarreal , Mao‐Draayer, Yang , Mishra, Murli , Tisavipat, Nanthaya , Tajfirouz, Deena , Tillema, Jan-Mendelt , López‐Chiriboga, A. Sebastian , Palace, Jacqueline , Chen, John J. , Boutiere, Clemence , Audoin, Bertrand , Champsas, Dimitrios , Vasileiou, Eleni , Sotirchos, Elias S , Henderson, Amanda D , Wilf-Yarkoni, Adi , Stiebel-Kalish, Hadas , Maillart, Elisabeth , Bonelli, Laura , Deschamps, Romain , Jitprapaikulsan, Jiraporn , Moss, Heather E , Villarreal Navarro, Sylvia E , Mao-Draayer, Yang , Mishra, Murli , Vorasoot, Nisa , Cacciaguerra, Laura , Tisavipat, Nanthaya , Tajfirouz, Deena , Tillema, Jan‐Mendelt , Lopez-Chiriboga, A Sebastian , Palace, Jacqueline , Hacohen, Yael , Pittock, S J , Flanagan, E P , Chen, John J , Levy, Michael , Shah, Shailee , Lotan, Itay , Thakolwiboon, Smathorn , Hewitt, Sage, Henderson, Amanda D. , Stiebel‐Kalish, Hadas , Vorasoot, Nisa , Cacciaguerra, Laura , Hacohen, Yael , Pittock, Sean J. , Flanagan, Eoin P.

Mayo Clinic

Neurology | August 29, 2025 | Volume: 105 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000213903 | PMID 40882166 Get It

Conventional versus advanced imaging selection for endovascular treatment of basilar artery occlusion strokes
Chen, Huanwen , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Grossberg, Jonathan A , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Mascitelli, Justin, Fragata, Isabel , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Matouk, Charles, Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Dağlıoğlu, Ergün , Williamson, Richard , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kan, Peter , Maier, Ilko , Jabbour, Pascal , Samaniego, Edgar A , Crosa, Roberto , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Fragata, Isabel , Colasurdo, Marco , Matsukawa, Hidetoshi , Cunningham, Conor M. , Kasab, Sami Al , Goyal, Nitin , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Osbun, Joshua W , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De , Chen, Huanwen

Mayo Clinic

European Stroke Journal | August 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/23969873251364973 | PMID 40873294 Get It

Introduction: Endovascular thrombectomy (EVT) is an effective treatment for basilar artery occlusion (BAO) stroke in select patients. While there is a growing body of literature suggesting that advanced imaging modalities such as computed tomography perfusion (CTP) and magnetic resonance (MR) may not be necessary for selecting anterior circulation large vessel occlusion stroke patients for EVT, whether advanced imaging may be superior to conventional imaging (non-contrast CT and CT angiography) in identifying good treatment candidates among BAO patients is less clear. Patients and methods: This was a multicenter retrospective cohort study of BAO EVT patients treated from 2013 to 2022 in the Stroke Thrombectomy and Aneurysm Registry. Patients selected for EVT by advanced imaging (CTP or MR) were matched with those selected by conventional imaging using propensity score matching (PSM) accounting for possible confounders. Primary outcome was functional independence at 90 days. Other outcomes include bedridden state or death at 90-days and symptomatic intracranial hemorrhage (sICH). Results: 268 patients were included. 150 patients were selected for BAO EVT by conventional imaging, 86 by CTP, and 32 by MR. Patients selected by advanced imaging were significantly older than those selected by conventional imaging (median age 71 vs 64 years, p = 0.001); patient characteristics were otherwise similar between cohorts. After PSM, 90-day outcomes were similar between the two cohorts ( p = 0.56), with similar rates of functional independence (39.4% vs 35.1%, p = 0.65), bedridden state or death (40.4% vs 44.7%, p = 0.66), and sICH (3.3% vs 5.7%, p = 0.49) for conventional and advanced imaging groups, respectively. Results were similar across treatment time windows (all p > 0.05). Conclusions: Selecting patients for basilar EVT using conventional versus advanced imaging did not result in different clinical outcomes, regardless of treatment time windows. Conventional imaging appears sufficient as a first-line tool for selecting basilar EVT patients in routine clinical practice.
Bridging language gaps in healthcare: a systematic review of the practical implementation of neural machine translation technologies in clinical settings
Karakuş, İbrahim Serhat , Strechen, Inna , Gupta, Ankita , Nalaie, Keivan , Chen, Christine L, Barwise, Amelia , Chen, Christine , Barwise, Amelia K , Chen, Christine L , Chen, Christine L, Hassett, Leslie C.

Mayo Clinic

Journal of the American Medical Informatics Association | August 27, 2025 | Volume: 32 | Issue: 11 | Pages: 1756-1766

10.1093/jamia/ocaf150 | PMID 40966445 Get It

Abstract Objectives Effective communication is crucial in healthcare, and for patients with a non-English language preference (NELP), professional interpreters are recognized as the gold standard in supporting bidirectional communication. However, interpreters are not always readily available, prompting the exploration of other options for translation and interpretation. The recent developments in artificial intelligence-based neural network translation tools, namely neural machine translation (NMT) may enable robust interpretation and translation. Materials and Methods We conducted a systematic review (SR) to evaluate the literature on NMT for this purpose. We did a comprehensive search of several databases with guidance from a professional librarian. The search was limited to the year 2000 onwards and English language. Title and abstract screening and full-text review were independently conducted by two reviewers with conflicts resolved by a third reviewer Results 2867 studies were identified with 10 studies included in the final analysis. Among these, six evaluated interpretation in real or simulated clinical settings and four examined translation of discharge materials. Google Translate and ChatGPT were assessed in several studies. Accuracy differed by language, with low-resource languages performing worse. Discussion NMT technologies in healthcare have several advantages including broad language accessibility and potential cost savings for institutions. Despite improved accuracy of these novel tools, due to possible critical errors NMT tools are not yet ready for widespread clinical use. Conclusion Future studies should focus on optimizing evaluation methods as well as how best to integrate these technologies into real-time clinical settings.
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension
Lópes, Renato D. , Cargill, Victoria A., Cowie, Martín , Cushman, William C. , Elkind, Mitchell S.V. , Epstein, Shilpi, Garg, Pushkal, Gersh, Bernard J. , Giakoumis, M. , Guo, Weinong, Kirtane, Ajay J. , Lefkowitz, Marty , Lesogor, Anastasia, Ohman, E. Magnus , Pagidipati, Neha J. , Reboussin, David M. , Roessig, Lothar, Roger, Véronique L. , Sánchez, Eduardo , Stockbridge, Norman, Weber, Michael A. , Whelton, Seamus P. , Lopes, Renato D , Cowie, Martin R , Cushman, William C , Elkind, Mitchell S V , Gersh, Bernard J , Giakoumis, Michail , Green, Jennifer B , Kirtane, Ajay J , Lefkowitz, Martin P , Mensah, George A. , O'Donoghue, Michelle L , Ohman, E Magnus , Pagidipati, Neha J , Roger, Veronique L , Sanchez, Eduardo J , Stockbridge, Norman , Touyz, Rhian M , Van Spall, Harriette G C , Weber, Michael A , Whelton, Seamus P , Hernandez, Adrian , Yancy, Clyde W. , Granger, Christopher B , Krychtiuk, Konstantin A , Chen, Roland K. , Ohman, E. Magnus, Touyz, Rhian M. , Spall, Harriette G.C. Van , Hernandez, Adrian F. , Granger, Christopher B.

Mayo Clinic

Hypertension | August 26, 2025 | Volume: 82 | Issue: 10 | Pages: 1599-1611

10.1161/hypertensionaha.125.24992 | PMID 40874957 Get It

Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox—blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.
Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Optic Neuritis With Venous Stasis Retinopathy
Saify, Mariya , Hur, Minjun, Guido, Fiorella Stefania, Selcen, Duygu , Chen, John J. , Chen, John J , Guido, Fiorella Stefania

Mayo Clinic

Neurology | August 25, 2025 | Volume: 105 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000214038 | PMID 40854174 Get It